

Hong Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6485347/publications.pdf>

Version: 2024-02-01

69
papers

675
citations

759233

12
h-index

677142

22
g-index

72
all docs

72
docs citations

72
times ranked

913
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. <i>Liver International</i> , 2011, 31, 1118-1126.	3.9	68
2	Seroprevalence and Risk Factors for Hepatitis B Infection in an Adult Population in Northeast China. <i>International Journal of Medical Sciences</i> , 2011, 8, 321-331.	2.5	61
3	Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, 175-182.	5.8	46
4	Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids. <i>Gut</i> , 2019, 68, 1311-1322.	12.1	44
5	Type III interferon-induced CBF β inhibits HBV replication by hijacking HBx. <i>Cellular and Molecular Immunology</i> , 2019, 16, 357-366.	10.5	33
6	Prevalence and Etiology of Abnormal Liver Tests in an Adult Population in Jilin, China. <i>International Journal of Medical Sciences</i> , 2011, 8, 254-262.	2.5	29
7	Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. <i>Frontiers in Pharmacology</i> , 2018, 9, 849.	3.5	23
8	Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1664-1669.	2.2	17
9	Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y ₁₂ Antagonist, in Healthy Chinese Volunteers. <i>Frontiers in Pharmacology</i> , 2018, 9, 643.	3.5	17
10	Tolerability, pharmacokinetics and antiviral activity of rHSA/IFN β 2a for the treatment of chronic hepatitis B infection. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1056-1071.	2.4	16
11	Randomised clinical trial: safety, efficacy and pharmacokinetics of HS β 10234 versus tenofovir for the treatment of chronic hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 243-252.	3.7	16
12	Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. <i>Die Pharmazie</i> , 2019, 74, 688-693.	0.5	16
13	Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 615-623.	2.3	15
14	A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2020, 11, 01329.	3.5	14
15	Sulfation predominates the pharmacokinetics, metabolism, and excretion of forsythin in humans: major enzymes and transporters identified. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 311-322.	6.1	13
16	Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y ₁₂ inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1860-1874.	2.4	12
17	Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan α -Agonist, in Patients \geq 65 and \leq 65 Years With Type 2 Diabetes. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 789-796.	1.6	12
18	Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. <i>Antiviral Research</i> , 2020, 174, 104693.	4.1	11

#	ARTICLE	IF	CITATIONS
19	A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 167-174.	0.6	11
20	In vitro anti-hepatitis B and SARS virus activities of a titanium-substituted-heteropolytungstate. <i>Antiviral Research</i> , 2012, 93, 118-125.	4.1	10
21	Antiviral effects of a niobium-substituted heteropolytungstate on hepatitis B virus-transgenic mice. <i>Drug Development Research</i> , 2019, 80, 1062-1070.	2.9	10
22	Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia. <i>Clinical Therapeutics</i> , 2020, 42, 276-285.	2.5	10
23	Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 185-192.	4.1	10
24	Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 263-269.	4.1	10
25	Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1169-1175.	1.8	9
26	Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects. <i>Hepatology International</i> , 2017, 11, 390-400.	4.2	8
27	Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations. <i>Chemical and Pharmaceutical Bulletin</i> , 2017, 65, 524-529.	1.3	8
28	Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects. <i>Antiviral Research</i> , 2020, 184, 104956.	4.1	8
29	Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimtasvir phosphate in patients infected with hepatitis C virus. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 855-864.	2.4	7
30	A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra [®]) in Chinese healthy subjects. <i>Annals of Medicine</i> , 2021, 53, 375-383.	3.8	7
31	A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men. <i>Frontiers in Pharmacology</i> , 2020, 11, 609522.	3.5	7
32	Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 1372.	3.5	6
33	S-amlodipine-bisoprolol combination therapy caused elevated transaminases and triglyceride levels in healthy Chinese subjects: a randomized controlled, open-label, multiple-dose pharmacokinetic interaction study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 687-695.	3.3	6
34	Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 1073-1080.	1.6	6
35	Safety and pharmacokinetics of a new biosimilar trastuzumab (HLO2): a Phase I bioequivalence study in healthy Chinese men. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 179-186.	3.1	6
36	Association of Estrogen Receptor Gene Polymorphisms and Primary Biliary Cirrhosis in a Chinese Population. <i>Chinese Medical Journal</i> , 2015, 128, 3008-3014.	2.3	5

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2018, 40, 1556-1566.	2.5	5
38	Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter 2, in people with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 191-202.	4.4	5
39	Pharmacokinetics and safety profiles of novel diethylstilbestrol orally dissolving film in comparison with diethylstilbestrol capsules in healthy Chinese male subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 407-415.	0.6	5
40	Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 373-384.	1.6	4
41	LBP-25-a phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b (chb) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study. <i>Journal of Hepatology</i> , 2019, 70, e153-e154.	3.7	4
42	Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2020, 42, 448-457.	2.5	4
43	A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects. <i>Frontiers in Pharmacology</i> , 2021, 12, 675358.	3.5	4
44	Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT ₆ Receptor Antagonist, HEC30654, in Healthy Chinese Subjects. <i>Frontiers in Pharmacology</i> , 2021, 12, 726536.	3.5	4
45	Single-Dose Pharmacokinetic Properties, Bioavailability, and Tolerability of Two Lamivudine 100-mg Tablet Formulations: A Randomized Crossover Study in Healthy Chinese Male Subjects. <i>Clinical Therapeutics</i> , 2013, 35, 1546-1556.	2.5	3
46	Inhibition of HCV 5 α -NTR and Core Expression by a Small Hairpin RNA Delivered by a Histone Gene Carrier, HPhA. <i>International Journal of Medical Sciences</i> , 2013, 10, 957-964.	2.5	3
47	Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter 2 inhibitor, in Chinese people with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2316-2324.	4.4	3
48	Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotaliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 660-668.	1.6	3
49	Evaluation of reference-scaled average bioequivalence of two oral formulations of Abiraterone acetate in healthy Chinese subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2018, 56, 562-570.	0.6	3
50	Tolerability and efficacy of pegylated consensus interferon- β in the treatment of chronic hepatitis C. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 9-16.	1.8	2
51	Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. <i>Frontiers in Pharmacology</i> , 2021, 12, 636324.	3.5	2
52	Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of β ₁ receptor, 5-HT _{2A} receptor, and calcium channel, in healthy subjects. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 271-278.	4.1	2
53	Association of immune response parameters with virological response in hepatitis C virus patients treated with pegylated consensus interferon. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2016, 54, 163-171.	0.6	2
54	Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2018, 56, 434-442.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers. <i>Frontiers in Pharmacology</i> , 2021, 12, 794054.	3.5	2
56	Single- and Multiple-Dose Pharmacokinetics and Tolerability of Limaprost in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2015, 35, 151-157.	2.2	1
57	Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatid in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 267-276.	1.6	1
58	Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design. <i>CNS Drugs</i> , 2020, 34, 867-877.	5.9	1
59	A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Colimumab in Healthy Chinese Male Subjects. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 77-83.	4.1	1
60	Comparison of the Pharmacokinetics of Generic Versus Branded Obeticholic Acid in a Chinese Population: Effects of Food and Sex. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 797-806.	1.6	1
61	First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults. <i>Frontiers in Pharmacology</i> , 2021, 12, 689523.	3.5	1
62	LBP-07-Association of pharmacogenomics and pharmacokinetics with antiviral activity of Pradefovir for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2019, 70, e143-e144.	3.7	0
63	FRI-176-Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects. <i>Journal of Hepatology</i> , 2019, 70, e466-e467.	3.7	0
64	Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 505-513.	1.6	0
65	P202 - Population pharmacokinetic and pharmacodynamic properties of eptifibatid in the inhibition of platelet aggregation in healthy Chinese subjects. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, S83-S84.	2.2	0
66	Effect of moderate activity on liver function and serum lipid level in healthy subjects during the phase I clinical trial. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1217-1221.	3.3	0
67	A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. <i>Clinical Therapeutics</i> , 2020, 42, 892-905.e3.	2.5	0
68	A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects. <i>Frontiers in Pharmacology</i> , 2021, 12, 646171.	3.5	0
69	An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Acridinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. <i>Drugs in R and D</i> , 2022, 22, 35-42.	2.2	0